Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases. We are proud to announce Roche has entered into a definitive agreement to acquire Telavant.

About Us

Product Candidates

We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.

Our Team

Frank Torti

Frank Torti, MD

Chairman and Chief Executive Officer

Plus Sign

Bittoo Kanwar, MD

Bittoo Kanwar, MD

Chief Medical Officer

Plus Sign

Tiago Girao

Tiago Girão

Chief Financial Officer

Plus Sign

Amy Mahery

Amy Mahery

Chief Commercial Officer

Plus Sign

Srini Ramanathan

Srini Ramanathan, PhD

Chief Development Officer

Plus Sign

Navneet Alag

Navneet Alag

Governance

Plus Sign

Ameer Basrai

Ameer Basrai

CMC

Plus Sign

Telavant Joe Bishop

Joe Bishop

Governance

Plus Sign

Jason Chamberlain

Jason Chamberlain, PhD

Nonclinical Development

Plus Sign

Kristin Clement, PhD

Kristin Clement, PhD

CMC

Plus Sign

Caroline Cooper

Caroline Cooper

Clinical Operations

Plus Sign

Xaio-Dong Chen, PhD

Xiao-Dong Chen, PhD

CMC

Plus Sign

Jean Dodge

Jean Dodge, PharmD

Pharmacovigilance

Plus Sign

Craig Dyar

Craig Dyar, PhD

Quality

Plus Sign

Eric Gaukel

Eric Gaukel

Nonclinical Development

Plus Sign

Abe Germansderfer

Abe Germansderfer

CMC

Plus Sign

Hilary Hafeken

Hilary Hafeken

Regulatory

Plus Sign

Anne Hansen

Anne Hansen

Data Management

Plus Sign

Coleenique Jefferson

Coleenique Jefferson

Clinical Operations

Plus Sign

Reed Johnson

Reed Johnson

Program Management

Plus Sign

Jeremy Lathen

Jeremy Lathen

Program Management

Plus Sign

Yin Lee

Li-Yin Lee, PhD

Biostatistics

Plus Sign

Peter Noolandi

Peter Noolandi

CMC

Plus Sign

Lee O'Brien

Lee O’Brien, PhD

Regulatory

Plus Sign

Marie Parrish

Marie Parrish, PhD

Regulatory

Plus Sign

Telavant Daniel Patterson PhD

Dan Patterson, PhD

CMC

Plus Sign

Sudhir Penugonda

Sudhir Penugonda, MD

Clinical Development

Plus Sign

Chrissa Rizk

Chrissa Rizk

Clinical Operations

Plus Sign

Victoria Silva

Victoria Silva, PhD

CMC

Plus Sign

Winston Su

Winston Su, PharmD

Regulatory

Plus Sign

Suzanne Vyvoda

Suzanne Vyvoda

Clinical Operations

Plus Sign

Eric Wasserstrum

Eric Wasserstrum

Governance

Plus Sign

Emily Weng

Emily Weng, ScD

Biometrics & Data Science

Plus Sign

Agata Woldanski

Agata Woldanski

Data Management

Plus Sign

Yan Xin

Yan Xin, PhD

Clinical Pharmacology

Plus Sign

Frank Torti

Frank Torti, MD

Chairman and Chief Executive Officer

Plus Sign

Irena Melnikova

Irena Melnikova, PhD

Director

Plus Sign

Telavant Eric Venker

Eric Venker, MD

Director

Plus Sign

Jay Zhou

Jay Zhou

Programming

Plus Sign